StockData
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. (APRE) stock

APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$0.45+0.05 (+11.52%)

Close on Nov 17, 2026Market cap $5.71MP/E –Yield –

Aprea Therapeutics cash

Cash and short-term investments held at the end of each period.

Aprea Therapeutics's cash was $41.23M at Jun 30, 2026. For fiscal 2025 it was $14.60M, down 36.2% from the year before. The highest annual figure on record is $130.09M in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.60M-36.2%
FY2024Dec 31, 2024$22.89M+5.7%
FY2023Dec 31, 2023$21.65M-24.8%
FY2022Dec 31, 2022$28.79M-45.8%
FY2021Dec 31, 2021$53.08M-40.4%
FY2020Dec 31, 2020$89.02M-31.6%
FY2019Dec 31, 2019$130.09M+98.1%
FY2018Dec 31, 2018$65.68M+169.1%
FY2017Dec 31, 2017$24.40M+78.6%
FY2016Dec 31, 2016$13.67M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$41.23M+149.4%
Q1 FY2026Mar 31, 2026$46.47M+141.1%
Q4 FY2025Dec 31, 2025$14.60M-36.2%
Q3 FY2025Sep 30, 2025$13.72M-47.7%
Q2 FY2025Jun 30, 2025$16.53M-42.4%
Q1 FY2025Mar 31, 2025$19.28M-40.5%
Q4 FY2024Dec 31, 2024$22.89M+5.7%
Q3 FY2024Sep 30, 2024$26.25M+3.5%
Q2 FY2024Jun 30, 2024$28.69M+3.6%
Q1 FY2024Mar 31, 2024$32.37M+4.4%
Q4 FY2023Dec 31, 2023$21.65M-24.8%
Q3 FY2023Sep 30, 2023$25.35M-23.4%
Q2 FY2023Jun 30, 2023$27.69M-29.1%
Q1 FY2023Mar 31, 2023$31.00M-35.0%
Q4 FY2022Dec 31, 2022$28.79M-45.8%
Q3 FY2022Sep 30, 2022$33.11M-46.1%
Q2 FY2022Jun 30, 2022$39.06M-44.0%
Q1 FY2022Mar 31, 2022$47.65M-38.6%
Q4 FY2021Dec 31, 2021$53.08M-40.4%
Q3 FY2021Sep 30, 2021$61.43M-39.3%
Q2 FY2021Jun 30, 2021$69.80M-38.2%
Q1 FY2021Mar 31, 2021$77.62M-36.6%
Q4 FY2020Dec 31, 2020$89.02M-31.6%
Q3 FY2020Sep 30, 2020$101.15M+93.3%
Q2 FY2020Jun 30, 2020$112.86M+85.0%
Q1 FY2020Mar 31, 2020$122.51M+86.5%
Q4 FY2019Dec 31, 2019$130.09M+98.1%
Q3 FY2019Sep 30, 2019$52.33M+323.6%
Q2 FY2019Jun 30, 2019$60.99M+150.0%
Q1 FY2019Mar 31, 2019$65.68M+380.7%
Q4 FY2018Dec 31, 2018$65.68M–
Q3 FY2018Sep 30, 2018$12.35M–
Q4 FY2017Dec 31, 2017$24.40M–
Q4 FY2016Dec 31, 2016$13.67M–

More Aprea Therapeutics figures

See a number that looks wrong?